Rocket Pharmaceuticals Class Action Lawsuit
Analysis based on 16 articles · First reported Jun 12, 2025 · Last updated Jun 25, 2025
The market is impacted by the significant drop in Rocket Pharmaceuticals' stock price due to the clinical hold on its key drug candidate and the subsequent class action lawsuit. This event highlights the risks associated with biotechnology investments, particularly in late-stage clinical trials and regulatory compliance.
Rocket Pharmaceuticals, a late-stage biotechnology company, is facing a class action lawsuit for allegedly violating the Securities Exchange Act of 1934. The lawsuit, led by Robbins Geller Rudman & Dowd LLP LLP, claims that Rocket Pharmaceuticals made false and misleading statements and concealed material adverse facts regarding its RP-A501 Phase 2 pivotal trial for Danon disease. Specifically, Rocket Pharmaceuticals amended the trial protocol to include a novel immunomodulatory agent without informing shareholders, which allegedly led to Serious Adverse Events, including the death of a participant. Following this, the United States — Food and Drug Administration placed a clinical hold on the study, causing Rocket Pharmaceuticals' stock price to fall significantly. Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, have until August 11, 2025, to seek appointment as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard